FilingsTodayDaewon Pharmaceutical
At a glance
Daewon Pharmaceutical filed 26 disclosures in the last 12 months, including 2 insider. The most recent key filing was on Jun 10.
Revenue for 2025 was ₩605B, up 1.2% on 2024. Operating margin was 0.6% against 4.7% a year earlier. Debt was 123% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩311B and operating profit of ₩4.4B.
The 2025 annual report lists 1,349 employees with an average tenure of 6.7 years and average pay of ₩77.3M, #432 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩288M each on average. It paid ₩250 per common share in cash dividends, against ₩300 a year earlier (-16.7%). 백승열 and related parties held 37.69% at year end.
From the 2025 annual report
Staff: 1,349 (925 men, 424 women), of whom 36 on fixed-term contracts. Total pay for the year: ₩117B. Directors and auditors: 6, paid ₩1.7B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩250 | ₩300 | ₩300 |
| Payout ratio | - | 45.3% | 26.6% |
| Yield (as filed) | 2.10% | 2.10% | 1.90% |
| Total cash dividends | ₩5.4B | ₩6.4B | ₩6.4B |
Largest shareholder
백승열 holds 11.34%; with 11 related parties the group holds 37.69% of common shares at year end.
Individuals paid ₩500M or more
| 백승호 회장 | ₩584M |
| 백승열 부회장 | ₩522M |
| 백인환 사장 | ₩521M |
Auditor: 예지회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.